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Ophthalmic gels: past, present and future 
 
1 Introduction 
The organ of vision “the eye” is one of the most confined, yet complicated, organs of the 
body. The eye can be divided anatomically into precorneal area, anterior and posterior 
segments (Figure 1). Each region is susceptible to a number of diseases that may require 
treatment via different routes of administration, using various modalities (Figure 1) [1]. 
 
Figure 1 Cross section of human eye showing the eye anatomy along with a list of common eye diseases, 
routes of drug administration, ophthalmic dosage form and delivery systems 
Static, dynamic and metabolic barriers of the eye make topical drug administration rather 
challenging. Static barriers are the physical stumbling blocks that drugs must overcome to 
exert a pharmacological effect on the eye; they include the conjunctiva, sclera and cornea.  
These barriers pose a challenge due to their different characteristic features (thickness, 
polarity, collagen content, hydrophilicity, surface charge etc). The conjunctiva has always 
been perceived as a major site of loss through which topically administered drugs end up in 
the systemic circulation rather than acting on the eye. The sclera has been shown to be 
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more permeable to hydrophilic drugs; on other hand the corneal epithelium is more in 
favour of lipophilic drugs [2]. Dynamic barriers are best represented by the clearance of the 
drug from the eye via conjunctival blood vessels, lymph vessels and nasolacrimal drainage. 
The human eye contains metabolic enzymes, such as esterase and carbonic anhydrase, that 
can deactivate drugs [3]. Collectively, these mechanisms lead to reduced precorneal 
residence time, compromised ocular absorption and bioavailability, necessitating frequent 
drug administration, often leading to poor patient compliance.  
Conventional ophthalmic dosage forms such as eye drops (formulated as solutions or 
suspensions) and ointments are preferred to deliver drugs to the ocular surface and the 
anterior eye segment. Their relative ease of use, non-invasiveness, low production cost and 
ease of manufacturing provide distinct advantages [4, 5]. However, aqueous eye solutions 
suffer very short contact time with the ocular surface due to rapid nasolacrimal drainage, 
leading to poor ocular bioavailability. Suspensions often give rise to unpredictable and 
variable ocular bioavailability; whereas ointments compromise visibility and lack patient 
acceptability, may induce reflex blinking and can result in the closure of the puncta and 
canaliculi [6]. 
The major problem with topical ocular therapeutics is the attainment of an optimal drug 
concentration at the target site. To overcome this, formulation scientists have researched 
and developed various drug delivery systems with enhanced ocular residence time [1, 7, 8]. 
Examples of such systems are medical gels, which have attracted considerable interest since 
the first produced soft contact lenses and implantable material prepared from hydroxyethyl 
methacrylate polymer in the 1960's [9]. More recently, in situ polymeric gelling systems 
(also called gel-forming systems) are being investigated for enhanced ocular drug delivery. 
These are prepared as liquid dosage forms which undergo phase transition on the ocular 
surface or conjunctival cul-de-sac to form a viscoelastic gel in response to an environmental 
stimulus, following topical application [10]. The environmental stimuli can be sub-divided 
into three main categories; physical (light and temperature) [11, 12], chemical (pH, redox 
potential, electrolyte- or molecular triggered response) [13, 14] and biological (biomolecules 
such as enzymes), each with a different mechanism for gel formation (outlined in Section 2) 
[15, 16]. These triggers can be modified to control gel formation, ocular residence time and 
drug release. In situ polymeric gelling systems have gained considerable interest as they do 
not require organic solvents or copolymerisation agents to trigger gel formation. 
 
2 Ophthalmic gelling systems: polymers and mechanisms   
The polymers used in preformed ophthalmic gels could be natural or semi-synthetic. Those 
used to form in situ gelling systems can be categorised, according to the environmental 
stimuli that triggers their conversion from sol to gel, as temperature-responsive 
(thermoresponsive), pH or ion-responsive gelling systems. 
2.1 Thermoresponsive polymers 
Thermoresponsive polymeric gelling systems are liquid at room temperature (20-25°C) and 
undergo a phase change, to form a gel, at 33.8°C on the ocular surface [17]. The 
temperature-dependent phase transition occurs when the thermoresponsive polymer in the 
solution becomes insoluble above or below a specific temperature, known as the lower 
critical solution temperature (LCST) and the upper critical solution temperature (UCST), 
respectively. Thermoresponsive systems which form above the LCSTs are often used in 
modified drug release applications, especially for protein delivery [18, 19].  
2.1.1 Mechanism of gel formation 
Thermoresponsive systems which form above LCSTs start as transparent, homogenous, free-
flowing, polymeric solutions at temperatures below the LCST and become cloudy upon 
reaching the LCST. The cloudiness of the solution results from the collapse of the polymeric 
chains followed by aggregation and subsequently increased light scattering of the solution. 
Phase separation occurs past the LCST, dividing the solution into a gel-phase and a solvent 
phase, commonly water [20]. This is primarily due to an entropy effect, favouring phase 
separation which occurs upon temperature increase [21]. There are multiple variables that 
can be fine-tuned to obtain the desired LCST. Deen [22] has reported a change of the LCST 
of poly(N-acryloyl-N′-ethyl piperazine-co-methyl methacrylate) after modifying the 
monomer composition, pH and the addition of salts or cationic surfactants.  
2.1.2 Thermoresponsive polymers of clinical potential 
Thermoresponsive polymers which have extensive ophthalmic applications can be broadly 
classified into poly(N-isopropylacrilamide) (PNIPAM), poloxamers and cellulose derivatives. 
These polymers are used as single or combination systems. PNIPAM is the most widely used 
thermoresponsive polymer and has an LCST of 32°C, above which a phase transition occurs 
transforming the water-soluble liquid to a hydrophobic gel [21]. This type of 
thermoresponsive polymer has multiple applications including tissue engineering [23, 24] 
and surface modification for biological applications (e.g. thermoresponsive control of cell 
attachment and detachment [25]). For ophthalmic applications, PNIPAM has been used as a 
platform for controlled drug delivery [26] and has been reported to reduce intraocular 
pressure following in vivo topical [26, 27] or intravitreal [28] administration. Furthermore, 
the use of linear PNIPAAm crosslinked with nanoparticles as a mixture has shown greater 
intraocular pressure-lowering effect relative to a linear PNIPAAm system [26]. Other studies 
have investigated preparation and characterisation of PNIPAM mixtures for refining 
PNIPAM’s mechanical properties. One such example is PNIPAM monomer crosslinked with 
N,N′-methylenebisacrylamide to form a hydrogel system composed of two PNIPAM 
networks. This system showed improved controlled release of bovine serum albumin [29]. 
Other studies which have fabricated PNIPAM and shown improved mechanical properties 
include polyethylene glycol (PEG)-conjugated-PNIPAM [30], poly(hydroxyethyl 
methacrylate)- conjugated-PNIPAM [31] and PNIPAM hydrogels containing poly(N-
isopropylacrilamide)-block-poly(methyl methacrylate) micelles [32]. However, when 
fabricating PNIPAM mixture systems, it is important to assess the shrinking-re-swelling cycle 
to determine the stability of the system [29, 33].    
Another class of thermoresponsive polymers, which are widely used in ophthalmic 
preparations, are the poloxamers. These are non-ionic amphiphilic triblock copolymers 
known as polyoxyethylene-poly-oxypropylene-polyoxyethylene or PEOA–PPOB–PEOA and are 
composed of a central hydrophobic unit of polyoxypropylene (PPO)(B) and two adjacent 
hydrophilic chains of polyoxyethylene (PEO)(A) [34]. Poloxamers are commercially available 
as Pluronics® and vary in their properties by their molecular weights and ethylene oxide-to-
propylene oxide weight ratios [20]. For example, pluronic F127 has a molecular weight of 12 
kDa and contains approximately 70% ethylene oxide, which contributes to its hydrophilicity 
and water solubility. It has a greater solubility in cold water relative to warm water, because 
of greater hydrogen-bond interactions and solvation at lower temperatures. The 
thermoreversible properties depend on the concentration of the poloxamer as well as the 
temperature, where solutions of concentrations higher than 20% w/w at temperatures 
exceeding 25°C have been reported to exhibit thermoreversible properties [35]. These 
thermoreversible properties coupled with gel formation at low temperatures restrict the 
ophthalmic application of pluronic F127 [36]. However, it has been shown to improve ocular 
drug permeation and hence improve the bioavailability of drugs [37]. Moreover, pluronic 
F127 displays optical clarity and has mucomimetic and protective properties, making it 
suitable for use as artificial tears [38]. To establish more applications for poloxamers, 
researchers tried to reduce their concentration and increase the phase transition 
temperature from ambient (25°C) to precorneal (33.8°C) temperature. One study achieved 
this by adding carbopol 974P (poly (acrylic acid) (PAA)), a pH-responsive gelling system 
generically known as carbomers (Section 2.2.2.), to the poloxamer 407 or 188 gelling 
systems. Gelation temperatures for these systems were in the range of 31.21-36.31°C. This 
combination provided additional benefits, such as enhanced drug solubility and 
mucoadhesive properties [39]. PAA has also been grafted onto pluronic F127 and showed 
prolonged precorneal residence time and improved ocular drug bioavailability [40]. Another 
study demonstrated reduced phase transition temperature and concentration of the 
poloxamer in combination with alginate [41].  
Cellulose derivatives such as methylcellulose (MC),carboxymethylcellulose sodium (CMC) 
and hydroxypropyl methylcellulose (HPMC) are naturally occurring polymers with 
thermoresponsive properties. They are commercially available in various products for the 
treatment of dry eyes, including Murocel® (MC), Celluvisc® (CMC sodium) and Ultra Tears® 
(HPMC). However, unlike poloxamers, MC and HPMC aqueous solutions form gels at lower 
concentrations (1-10%) [42] and temperatures of 40-50°C and 75-90°C, respectively [43]. 
The phase transition temperature of cellulose derivatives decreases with a higher degree of 
cellulose ether substitution or with the addition of salts [44, 45]. The sol-gel transition 
temperature of MC is also influenced by the salt type and MC concentration [46, 47]. 
Combining cellulose derivatives with poloxamers generates gelling systems with enhanced 
properties to favour ophthalmic drug delivery. For example, pluronic F-127 in combination 
with HPMC, as a viscosity enhancing agent, prolonged the ocular residence time of the drug 
[48, 49]. Other polymers which are under investigation as single preparations or in 
combination with the aforementioned thermoresponsive polymers, to enhance ocular drug 
delivery, include xyloglucan [50, 51] and chitosan [52, 53]. 
2.2 pH-responsive polymers  
pH-sensitive polymers contain ionisable groups allowing them to vary their solubility, 
undergoing sol-gel phase transition under different pH environments [54]. Cellulose acetate 
phthalate latex (CAP-latex) and carbomers (polyacrylic acid, PAA) are commonly studied pH-
responsive polymers. 
 
2.2.1 Mechanism of gel formation 
Ophthalmic formulations contain pH-responsive polymers, also known as polyelectrolytes, 
which undergo sol-gel phase transition in response to environmental pH changes (i.e. pH of 
preparation vs pH of lacrimal fluid). The sol-gel phase transition results from changes in the 
ionisation state of the weakly acidic (carboxylic or phosphoric) or weakly basic (ammonium) 
groups present in the polyelectrolyte [55]. The pH at which these groups ionise depends on 
their pKa values (3 – 10) [56] and the molecular weights of the polymers [57]. Changes in 
the ionisation state of these groups lead to changes in conformation and solubility, as well 
as swelling of the system [58]. The gelling mechanisms and properties of some pH-
responsive polymers are affected by the salt concentration, ionic strength and temperature. 
Horkay and Basser [59] showed that increasing the calcium concentration in a near-
physiological solution containing PAA induced reversible volume transition. Other studies 
have demonstrated sol-gel transition in response to pH, ionic strength and temperature 
stimuli [60-62].  
2.2.2 pH-responsive polymers used in ophthalmology  
A common pH-responsive polymer which is widely used in ophthalmic preparations is PAA, 
and its derivatives (Table 1). PAA, also known as carbomer® or carbopol® [63], is an anionic 
high molecular weight synthetic polymer composed of acrylic acid cross-linked with either 
allyl ethers of sucrose or allyl ethers of pentaerythrityl [64]. Ophthalmic preparations 
containing PAA are formulated at low pH values and form gels in the higher pH environment 
of the lacrimal fluid. This transition is also dependent on the molecular weight of the PAA, 
where polymers of molecular weights greater than 16.5 kDa have shown sol-gel phase 
transition, whereas those with lower molecular weights have not [65]. However, it is 
important to note that formulations outside of the pH range of 4-10 cause ocular irritation 
and damage [66].  
 
Table 1. Commercially available ophthalmic gel products. Adapted from [67]. 
PAA increases the viscosity of ophthalmic preparations but has also been reported to exhibit 
mucoadhesive properties [68] that further enhances ocular drug retention and delivery. 
These result from hydrogen bond formation between the carboxylic acid group of PAA and 
complementary functional groups of the mucus glycoprotein [69, 70] present in the 
conjunctiva and cornea [71] and is optimal at pH 4-6 [70]. To further improve the gelling 
properties and prolong drug release many studies have utilised a combination system, 
comprised of PAA with other viscosity enhancing agents; HPMC [72, 73] or MC [74]. PAA and 
MC have also been used to prepare pH-responsive interpolymer complexes or films with a 
tunable release for ophthalmic delivery of riboflavin [75].  
Polymer(s) Brand name  Company Therapeutic agent  
Carbomer 
  
Pilopine HS® Alcon Laboratories Pilocarpine 
Zirgan® Sirion Therapeutics  Ganciclovir 
Fucithalmic®  Concordia Int. Fusidic acid 
 
Carbomer 940 Pilogel®  Alcon Laboratories  Pilocarpine  
 
Carbomer 980 Lumecare® Carbomer 
Gel 
Viscotears®  
Xailin Gel®  
Clinitas Gel®  
GelTears®  
 
Medicom  
Alcon  
Nicox  
Altacor  
Bausch & Lomb 
Carbomer 980 
Carbomer 974P Liquivisc® Spectrum Thea Carbomer 974P 
 
Carbomer and 
polyvinyl alcohol 
  
Nyogel® Novartis Timolol 
Polycarbophil  
(carbomer 
crosslinked with 
divinyl glycol) 
DuraSite®/ Azasite® 
 
Azasite plus® 
Inspire Pharmaceuticals  
 
 
Azithromycin  
 
Azithromycin and 
dexamethasone 
Gellan gum Timoptic® XE Merck Timolol maleate 
Xanthan gum Timoptic® GFS Alcon Timolol maleate 
Hypromellose AktenTM Akten 
Lidocaine 
hydrochloride 
Carbomer  Virgan® 
Thea Pharmaceuticals 
Ltd 
Ganciclovir 
Polyethylene glycol ReSure® Sealant Ocular Therapeutix, Inc. Trilysine acetate 
 Pseudolatex-based polymeric dispersions ocular formulations have been assessed for 
sustained ocular drug delivery [76]. One such example is cellulose acetate hydrogen 
phthalate (CAP)-latex which is an ion-exchange liquid at pH 4.4 and undergoes rapid 
transition to form a stable gel upon contact with the lacrimal fluid (pH 7.2) [54]. This has 
been used in conjunction with HPMC to construct a reservoir-type ocular insert for 
controlled delivery of acyclovir [77]. Further, CAP has low viscosity, good ocular tolerance 
and improved bioavailability, reducing the frequency of topical application and potentially 
improving patient compliance [54]. Taking these factors into consideration, CAP has 
significant potential for ocular drug delivery. 
 
Various other pH-responsive polymers have also been investigated for ophthalmic 
applications, including chitosan, a pH-responsive polymer which also exhibits mucoadhesive 
[78] and permeation-enhancing [79, 80] properties, in combination with the 
thermoresponsive polymer (pluronic F-127) [81]. Others include; polyvinylacetal 
diethylaminoacetate [82] and poly(2-hydroxyethylmethacrylate-co-2-
(diisopropylamino)ethyl methacrylate) [83]. 
2.3 Ion-activated polymers 
2.3.1 Mechanism of gel formation 
Anionic polysaccharides crosslinked with monovalent (Na+) and/ or divalent (Mg2+ and Ca2+) 
cations found in the lacrimal fluid may initiate sol-gel transition and increase polymer 
viscosity. The increase in polymer viscosity is directly proportional to the cation 
concentration [84, 85]. Therefore, an increase in tear production to dilute the viscous 
solutions would consequently result in an increase in cation concentration and hence, 
greater polymer viscosity, enhancing drug ocular retention time, reducing nasolacrimal 
drainage and improving drug bioavailability [86]. Examples of widely used ion-activated 
polysaccharides include gellan gum (Gelrite®/Kelcogel®) and alginic acid.  
2.3.2 Ion-activated polymers used in ophthalmology 
Gellan Gum is a deacetylated anionic extracellular polysaccharide obtained from 
Pseudomonas elodea and is composed of repeating units of α-L-rhamnose, β-D-glucuronic 
acid and two β-D-glucuronic acid residues [87]. At room temperature, in aqueous solution, 
this polymer forms double helices that are connected via weak van der Waals forces. Once 
in contact with the cationic electrolytes of the lacrimal fluid, these helices aggregate leading 
to cross-linking of the polymer and forming complexes with the cations and hydrogen bonds 
with the water [88-90]. This results in a conjunctival-scleral depot which allows for more 
controlled release of drugs [91]. 
Alginic acid is a biodegradable and biocompatible anionic polysaccharide composed of β-D-
mannuronic acid and α-L-guluronic acid residues, linked by 1,4-glycosidic bonds, the 
sequence and proportions of which are determined by the algae source from which it is 
obtained [92, 93]. This polysaccharide increases the ocular drug residence time because of 
both its mucoadhesive nature and gel formation following the interaction of its guluronic 
acid residues with the Ca2+ ions of the lacrimal film [93-95]. The physicochemical 
characteristics of the formed gel are dependent on the concentration and viscosity of the 
alginate used, as well as the ratio of α-L-guluronic to β-D-mannuronic acid residues in its 
structure, increasing the content of the former would increase the extent of gelation [96].  
3 Characterisation of ophthalmic preformed gels and in situ gelling systems 
In addition to considering the effect of environmental stimuli in the development of in situ 
gelling systems, the polymers forming the gel must also have suitable characteristics for 
ocular application. These formulations should be biocompatible, safe, and biodegradable 
with no/minimal adverse effects. The formulation should have pseudoplastic flow with 
thixotropic characteristics, producing a low fluid viscosity under high shear rate conditions. 
This allows for ease of spreading across the ocular surface upon blinking and transforming 
to a highly viscous fluid under low shear rate conditions to prolong the ocular residence 
time [97]. Ideal properties of ophthalmic in situ gelling systems, together with their 
corresponding modes of investigation, are discussed below and summarised in Table 2.  
Table 2 Characteristics and mode of investigation of topical ophthalmic formulations 
including preformed gels and in situ gelling (gel-forming) systems. 
Characteristic Mode of investigation Reference(s) 
Clarity and optical 
transmittance 
Visual inspection and spectrophotometric 
analysis 
[98] 
 
 
Safety and good ocular 
tolerance 
Observation for possible adverse effects 
Visual acuity  
Ocular tolerance (Draize, HETCAM, BCOP and 
histology tests)  
Isotonicity test and cell-based cytotoxicity 
assays 
[99-101] 
 
[102, 103] 
Suitable pH Measurement of pH at 37°C [13, 104] 
 
Pseudoplastic and 
thixotropic flow 
Viscoelasticity 
Cone and plate rotational or oscillation 
viscometer 
[104-106] 
 
 
 
Gelling capacity Qualitative observation of gel formation in 
simulated tear fluid  
 
[104, 107] 
Mucoadhesive properties Polymeric mucoadhesion tests  [107-110] 
Bioadhesive force of the gel 
 
 
Prolonged ocular 
residence time 
Precorneal residence assessed using gamma 
scintigraphy  
 
[103, 111, 
112]  
 
Ease and reproducibility 
of application 
Gel consistency, firmness and cohesiveness 
assessed by texture analyser 
 
[113] 
Compatible excipients Fourier transform infrared spectroscopy used 
to analyse potential drug-polymer interactions 
 
[114] 
Physical properties  Solid-state properties elucidated by X-ray 
powder diffraction and particle size analysed 
by dynamic light scattering  
 
[115, 116] 
Sustained drug release In vitro dissolution studies 
 
[100] 
Enhanced transocular 
permeation 
Ex vivo transcorneal and transscleral 
permeation studies  
 
[7, 52] 
Sterility Direct inoculation method 
 
[117] 
Stability  Storage stability investigated [118] 
 
4 Hydrogel contact lenses  
Hydrogels are the main constituent in contact lenses due to their high water content and favourable 
properties that render them highly compatible with human tissues [119, 120]. Hydrogel contact 
lenses are not only used for vision correction or cosmetic purposes, but they are also used as drug 
delivery devices for extended delivery of ophthalmic medications. Contact lenses prolong the 
resident time of their drug cargo, control and extend their release to several days or even months 
and enhance their bioavailability to more than 50% (conventional eye drops would achieve 5-10% 
ocular drug bioavailability) [121, 122]. These drug-eluting contact lenses can be particularly 
beneficial for chronic and elderly patients having trouble adhering to repeated dosage regimens 
characteristic of conventional eye drops where extensive treatment of serious conditions such as 
glaucoma, corneal ulcers or infections is required [123]. Moreover, drug delivery via hydrogel 
contact lenses can lead to reduced drug doses and thus side effects [124].  Several in-vivo studies, 
through animal models and small human trials, have proved the effectiveness of contact lenses as a 
drug delivery platform with improved clinical outcomes compared to conventional eye drops [125]. 
Contact lenses made from the hydroxyethyl methacrylate (HEMA) and its copolymers were used to 
extend the delivery of drugs to the eye for up to 1 week; drugs include timolol [121, 126], 
dexamethasone [127, 128], lidocaine [129, 130] and antifungal drugs [131, 132] .  Other monomers 
including methacrylic acid (MAA), methyl methacrylate, poly (vinyl alcohol) (PVA) and N-vinyl-2-
pyrolidone (NVP) can be incorporated into the hydrogel matrix to enhance the wettability of the lens 
or to increase drug loading. [133]. For extended wear contact lenses, silicone hydrogels are used due 
to their high oxygen permeability compared to other polymeric hydrogels. The release of drugs from 
silicone hydrogel lenses can be extended from 20 days to 3 months by adjusting the ratio of the 
hydrophilic to the hydrophobic monomers incorporated [126]. 
Several methods have been employed to incorporate drugs in hydrogel contact lenses; the simplest 
method is soaking the lens in the drug solution [134, 135], where the drug is entrapped in the 
internal channels of the hydrogel. The soaking method is straightforward and cost-effective, it can 
be done with commercially available contact lenses or specially synthesised contact lenses from 
various polymer combinations [136]. However, the soaking technique is limited only to low 
molecular weight and hydrophilic drugs and suffer from low drug loading and fast release of the 
drug from the lens, mainly via diffusion [134, 137]. Vitamin E is an effective biocompatible diffusion 
barrier that can be used to prolong the release of the loaded drugs; it has proven to enhance drug 
stability and limit diffusion during storage [138]. Moreover, vitamin E acts as a UV barrier and can 
reduce water dehydration from the hydrogel lens [139].   
To be able to incorporate lipophilic therapeutics, maximise drug loading and prolong the release 
from hydrogel lenses, several approaches have been employed including the addition of complexing 
agents such as β-cyclodextrin [140], surfactant aggregates [141] and nanoparticles [142, 143].  
Molecular imprinting can offer another solution, through creating voids within the hydrogel 
macromolecular network with high affinity to the targeted drug, thus increasing the loading capacity 
and offering better control over the release of the incorporated drug [122]. The main drawback of 
molecular imprinting is the difficulty to incorporate more than one drug and the high degree of 
hydrogel crosslinking required, which might alter the physical properties or the oxygen permeability 
of the hydrogel lens [144]. Other approaches using multilayer contact lenses, sandwiching a drug-
loaded PLGA polymer film between two layers of pHEMA hydrogel, were able to extend the release 
of the loaded drug for up to 1 month [131, 145].    
5 Assessing the ocular tolerability of ophthalmic gels 
Given the nature of the polymers, materials and excipients that are used in the preparation of 
ophthalmic dosage forms, it is paramount that any new eye formulation intended for topical ocular 
application, including ophthalmic gels, is investigated for potential toxicity/adverse effects on ocular 
tissues. Several tests and assays are adopted by various regularity bodies to determine the ocular 
toxicity and irritation potential of the used polymers; the most widely used tests are summarised 
below.  
“Draize rabbit eye irritation test” is the oldest eye irritation test that was developed by Draize et al. 
in 1944 and is still widely used and approved by the Organisation for Economic Co-operation and 
Development (OECD) and the FDA to evaluate potential ocular irritation [146]. This test uses live 
rabbits (normally six rabbits) for the determination of the whole range of possible eye irritation 
effects from chemical substances. The irritation responses include; redness, swelling, oedema, 
cloudiness, discharges, haemorrhage and blindness [102, 147-149]. The test materials are classified 
based on a subjective scoring, from non-irritating to severely irritating, for their effect on the cornea, 
iris and conjunctiva [147].  
 
Although the Draize test is still approved by many regulatory bodies, concerns have been expressed 
on ethical grounds [150]. The stress level and pain sensation caused by the test with the long 
duration of recovery and the need for large numbers of live rabbits have been criticised by animal 
welfare groups [150]. The main shortcomings of the Draize test is its subjectivity, poor 
reproducibility and the differences between the rabbit eye and the human eye [151]. Therefore, new 
tests were proposed based on recommendations of the National Research Council to refine the 
Draize irritation test and address the issues arising from it [102]. One of these tests is the low-
volume eye irritation test (LVET), which was developed by Griffith et al.(1980) [152]. The test is a 
modified Draize test in which the number of test material is reduced while maintaining the same 
scoring system of the Draize test [152, 153]. Although LVET overcame some of the Draize test 
drawbacks, LVET is still criticised by animal welfare groups for the use of live animals. Moreover, if a 
negative irritation result is obtained using the lower amount, the standard procedure of the LVET 
requires increasing the amount of the test material and thus can reach the same level as the normal 
Draize test  
Regulatory bodies have adopted a battery of in vitro and ex vivo irritation tests that can potentially 
replace the former controversial in vivo eye irritation tests. The developed test needed to be 
accurate and reproducible without the use of live animals. Over the past decade, numerous irritation 
assays were successfully developed and tested, amongst which are the isolated/ enucleated organ 
method such as the Bovine Corneal Opacity and Permeability (BCOP) test, the non-ocular 
organotypic models such as Hen's Egg Test on the Chorioallantoic Membrane (HET-CAM), and the 
cell-based cytotoxic colorimetric methods such as Red Blood Cell (RBC) lysis and protein 
denaturation, Neutral Red Uptake (NRU) and Sulforhodamine B (SRB) assays. [154]. 
The BCOP test works by using ocular organotypic modules, which maintains (for a short time) the 
normal biochemical and physiological function of the enucleated eye [155]. Corneal opacity and 
permeability (Figure 2) are the main two responses measured by the BCOP test. Corneal opacity 
gives an indication of protein denaturation, damage to the epithelial and stromal layers of the 
cornea, swelling and vascularisation; all of which result from exposing the cornea to the test 
substance [155].  
 
 
 
 
 
 
 
 
 
A B 
Figure 2 Change in bovine corneal opacity following the exposure to (A) Positive 
control which shows complete opacification of the cornea. (B) Negative control with 
no sign of corneal opacity change 
 Sodium fluorescein penetration gives an indication on the integrity of the corneal epithelial layer, 
damage by the test materials. Normally an intact and healthy cornea is completely impermeable to 
sodium fluorescein. The extent of the initial injury resulting from the test material correlates with 
the level of cell death. Therefore, the magnitude of the eye irritation is determined by the intensity 
of the initial injury [102]. As such, substances that damage the superficial corneal epithelial layer are 
classified as slightly irritant; substances that penetrate the corneal epithelium and stroma to reach 
and damage the endothelial layer of the cornea are classified as severe irritants; whilst substances 
that damage the epithelium and penetrate further to affect the stroma are classified as mild / 
moderate irritants.  
 
 
 
 
 
 
 
 
 
 
A histopathological examination of the corneal tissue after exposure to the investigated ophthalmic 
gel can provide a more comprehensive insight on the degree and depth of the corneal injury at 
cellular levels [156, 157]. The diffusion of the gel comprising materials (polymer, solvent, ions, and 
drug) through the main layers of the cornea (epithelium, stroma and endothelium) depends on the 
degree of the corneal injury. The corneal tissues are stained with Hematoxylin and Eosin (H&E stain), 
and signs of corneal damage are inspected, these include; epithelial injuries and stromal oedema. 
Such damages are perceived as sources of ocular irritation post topical treatment with the test 
material. Characteristic epithelial injuries that are documented and scored include cell loss, 
vacuolisation, nuclei coagulation (pyknosis) and Bowman’s membrane cell separation (Figure 4) 
[150, 158]. Swelling, vacuolisation and pyknosis of keratocytes are the main characteristic features 
of stromal lesions [150, 158]. 
 
 
 
 
A B 
Figure 3 Fluorescein stained bovine’s eye following the exposure to (A) Positive control 
which shows complete permeation of the fluorescein dye. (B) Negative control with no 
sign of fluorescein permeation 
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Figure 4 Histopathological documentation of H&E stained bovine cornea post exposure to an 
ocular insult. (A) Characteristic epithelial injuries that are observed and scored. (B) Negative 
control which shows normal histopathology of the cornea 
The HET-CAM assay is another test that is widely used to assess the ocular irritation of ocular gels. 
The CAM is a vascularised respiratory membrane that surrounds the fertilised bird embryo; it has a 
network of arteries, veins and capillaries. The inflammatory responses of this blood vessel network 
to the gel formulation are similar to those of the conjfunctival tissue. As such, regulatory bodies 
recognise and accept the HET-CAM as a conjunctival model for the irritation test of ocular 
formulations including ophthalmic gels and in situ gelling eye drops [14, 15]. The test is fast, simple, 
inexpensive and reproducible; it has been successfully used to assess the irritation effect of several 
pharmaceutical systems [6, 14, 16, 17]. 
 
 
 
 
 
 
 
 
 
RBC haemolysis assay has been used to test the irritation effect of substances. [159] This assay is 
fast, simple, and inexpensive with a defined endpoint that can be used as a screening method for 
potential irritation. The test is based on quantifying RBC haemolysis and protein denaturation of 
freshly isolated mammalian erythrocytes triggered by exposure to irritants that damage the cell 
membrane. [159-161] The cell membrane damage events in the RBC assay are well correlated to 
the initial inflammatory reaction and protein denaturation resulting in the corneal opacification due 
to the irritant effect of substances.[160] The oxyhaemoglobin (HbO2) released from the lysis of 
fresh red blood cells, due to the irritation effect, is measured using UV spectroscopy. The endpoint 
realtes to the concentration of the irritant materials that induces a 50% RBC lysis post exposure 
[160]. 
6 Newly developed ophthalmic gels and in situ gelling systems 
Novel hydrogels are interesting biomaterials that are used for ophthalmic applications including drug 
delivery or as replacement corneal membranes. Their hydrophilic nature and resembling consistency 
to living tissues allow them to be biocompatible. Unfortunately, clinical applications of smart gels are 
still limited. It would be more useful and economical to develop novel hydrogels that meet the 
requirements of the desired applications rather than trying to find applications for newly developed 
hydrogels. Moreover, developing smart gels that mimic natural systems can advance and broaden 
their therapeutic uses [162].  
Figure 5 HET-CAM model showing (A) Inflammatory responses used to score conjunctival 
irritation. (B) Negative control with no sign of inflammation  
Despite the development of a vast number of hydrogels that can be used for therapeutic purposes 
or medical applications, only a handful have been approved by the Food and Drug Administration 
(FDA) [162]. The FDA has set recommendations for assessing the safety of medical devices that can 
be relevant to hydrogel drug delivery systems including cytotoxicity, sensitization, 
hemocompatibility, pyrogenicity, genotoxicity, carcinogenicity, reproductive and developmental 
toxicity tests [163]. 
A recently developed gel for drug delivery applications was made from pure proteins. The hydrogel 
was produced by the simple interaction between two recombinant proteins, ULD-TIP1 and ULD-
GGGWRESAI. The porous protein hydrogels were evaluated by rheology, scanning electron 
microscopy (SEM) and cytotoxicity tests. Their degradation profile extended to 144 hours which is 
promising to extend the release of ophthalmic drugs [164].  
6.1 Stimuli-responsive gels  
Ophthalmic drug delivery via smart hydrogels, encompasses three types of stimuli; temperature, pH, 
and ions [165]. However, hydrogels can be stimulated by other environmental factors such as light 
[166], pressure [167, 168], thrombin [169, 170], antigen [171, 172], biomolecule [173, 174] or 
glucose [175, 176]. The unique properties of smart hydrogels open the door wide for novel 
applications including their potential use in ocular drug delivery. Currently, one of the critical 
limitations for the use of stimuli-responsive hydrogels in drug delivery is their delayed response time 
[177]. With further research and development of new hydrogels, this drawback can be overcomed.  
A novel stimuli-responsive gel was designed by Yu et al. (2016) for ophthalmic drug delivery. The 
hydrogel was made by chemical cross-linking of the biocompatible and pH-sensitive carboxymethyl 
chitosan (CMC) with the temperature-sensitive poloxamer 407 (F127) using glutaraldehyde as a 
crosslinking agent to form a pH-induced thermosensitive hydrogel that can undergo a reversible sol-
gel transition at a very low concentration. The gel maintained controlled release of a model drug and 
showed no cytotoxicity to human corneal epithelial cells [178].  
Pressure-responsive hydrogels, such as poly (N-isopropylacrylamide), poly (N-n-propylacrylamide), 
poly (N,N-diethylacrylamide) and poly (N-isopropylacrylamide) tend to collapse at low pressure and 
expand at high pressure [177, 179-181]. In the future, pressure sensitive gels can be explored for 
controlling the drug release profile to adjust the intraocular pressure in glaucoma patients; this area 
is still open for new products. It is worth noting that pressure-sensitive hydrogels show sensitivity to 
change in temperature, this might be explained by the increase in the lower critical solution 
temperature (LCST) of the gels with pressure [180]. 
Most currently available smart gels have drug release profiles that are limited for few days. Hence, 
the need to develop improved hydrogels that may control drug release over a period of few months 
[162]. Osswald et al. (2015) have successfully developed an injectable, thermo-responsive gel that 
sustained the release of a model protein drug for 200 days. The drug was encapsulated within 
poly(lactic-co-glycolic acid) (PLGA) microspheres that were in turn suspended in the poly(N-iso-
propylacrylamide) (PNIPA Am)-based hydrogel. The phase transition temperature of the hydrogel 
was maintained between 32 and 37 °C through adjusting the concentration of polyethylene glycol 
diacrylate (PEG-DA) in the cross-linking reaction [182].  
6.2 Nanoparticle-hydrogel composites 
The incorporation of ophthalmic drugs in nanocarriers has gained interest due to its potential to 
prolong ocular residence and sustain drug release. Furthermore, nanocarriers do not alter the 
transparency or the desirable ophthalmic characteristics like the case with suspensions or ointments 
[183]. Composites of polymeric nanoparticles in hydrogel matrices are appealing for controlled and 
extended delivery of hydrophobic drugs. The release profile of dexamethasone acetate was 
successfully prolonged from 3 to 30 days after loading into poly(ethylene glycol)- poly(ε-
caprolactone) (PEG−PCL) micelles prior to incorporation in the hydrogel [184].  
Novel biodegradable pentablock (PB) copolymer-based nanoparticles have proven to be effective in 
controlling and sustaining the release of loaded therapeutics to more than 100 days to treat 
posterior segment diseases. Polyglycolic acid-polycaprolactone-polyethylene glycol-
polycaprolactonepolyglycolic acid (PGA-PCL-PEG-PCL-PGA) and polylactic acid-polycaprolactone-
polyethyleneglycol-polycaprolactone-polylactic acid (PLA-PCL-PEG-PCL-PLA) are examples of PB 
copolymers that are non-toxic, non-immunogenic and biocompatible. The drug loading and release 
profiles of the loaded therapeutics can be controlled through altering the drug/polymer ratio and 
molecular weight, crystallinity and the block arrangement of the copolymers [185, 186]. To achieve 
constant zero-order release of their protein/peptides cargo, the PB nanoparticles were incorporated 
in biodegradable and injectable in situ thermosensitive hydrogels. The thermosensitive hydrogel 
offered high drug loading with minimum intravitreal injection volume, allowing for longer duration 
of action thus reducing complications and improving patient compliance. 
6.3 Nanogels 
Nanogels are hydrogels composed of a network of hydrophilic polymers and drug in the nanoscale 
range [187]. They can host the drug alone or when incorporated into liposomes, solid lipid 
nanoparticles, dendrimers or polymeric nanoparticles. Nanogels can hold large amounts of 
therapeutics by simple incorporation methods without altering the biological activity of their load 
[188], which can be useful for the delivery of peptides and antibodies. The hydrolytic degradation of 
the polymer network results in a sustained release of the entrapped drug [183]. The drug release 
from the nanogels can be controlled by adjusting the amount or type of polymers, charge on the 
drug or the nanogel, or via multiple environmental stimuli such as pH, temperature and ions [187, 
189]. The combined effects of multiple stimuli on the nanogel network structure offer improved 
control over the release of the entrapped therapeutic agent. This can allow for various drug release 
profiles from the same hydrogel [183].  Furthermore, nanogels have enhanced permeability and 
retention effect compared to macrogels, which makes them preferred for delivery of nucleic-acid 
based drugs, to cells [190].  
  
6.4 3D printed hydrogels 
6.4.1 Tissue and organ generation 
3D printing is a relatively new technology that allows the creation of physical three-dimensional 
objects with complex geometries from a computer-aided design (CAD) [191, 192]. The computer 
software splits the design into a series of thin horizontal cross-sections (slices) and sends them to 
the machine to print the designed structure layer-by-layer [193]. There is no need for fabrication 
moulds, which gives a high degree of freedom and flexibility in design such that structures that 
cannot be fabricated using conventional subtractive techniques can be made using 3D printing [194]. 
On the other hand, 3D bioprinting allows printing biomaterials to tissue analogue structures without 
any change in their mechanical or biological properties [195, 196]. 3D bioprinting is gaining 
increased interest in the medical field because it can fabricate tissues [197, 198], scaffolds [199], skin 
[200], cartilage [201, 202] and potentially, organs such as kidney and liver from human cells [203-
206]. Those 3D printed tissues and organs are currently used in drug research and development 
[207], in medical schools [208] and for surgical applications. Co-culturing human retinal endothelial 
cells (HRECs) and human retinal astrocytes (HRAs) on 3D hydrogel scaffolds provided a more 
accurate representation for the blood-retinal barrier compared to previous 2D cultures [209].  
3D bioprinting allows for the building of tissues and organs from the patient’s own cells or induced 
Pluripotent Stem Cells (iPSCs) which eliminate immune responses. It can be utilised as the as an 
optionfor organ replacement to compensate the shortage and difficulties associated with donor 
transplantations [196, 210, 211]. The most common types of bioprinting techniques are ink-jet 
printing, extrusion-based printing and laser-assisted printing. In case of the ink-jet printing, the 
cartridge is filled with the biomaterial, similar to the conventional way of printing, and the bioink 
droplets are forced out from the nozzle by air pressure pulses to be deposited on specific locations 
on a substrate. Ink-jet printing was used to pattern stem cells on polymer substrates and to 3D print 
single or multiple cell types in a precise arrangement pattern [211-213]. With extrusion-based 
technique, the bioink is extruded through sterile syringes to create 3D biostructures [195].  Large 
structures with high cell densities can be formed using extrusion-based 3D printing technique. 
However, the resolution of the formed structures (200 µm) are less than that from ink-jet printing 
(20-100µm) and the high shear stress created  when extruding the bioink through the tiny nozzle can 
affect cell viability [211]. Extrusion-based 3D printing technique was used to construct extracellular 
matrix of adipose, cartridge and heart tissues using human mesenchymal stem cells and embryonic 
stem cells [214, 215]. With laser-assisted bioprinting, the droplet of bioink is indirectly induced 
towards the substrate, with no mechanical stress, thus producing 3D printed constructs with high 
viability and resolution (5µm). Nevertheless, this technique is more expensive and time-consuming 
compared to the other techniques. 3D printed human osteoprogenitor cells and mesenchymal stem 
cells have been successfully printed using laser-assisted bioprinting technique [211, 216, 217].  
3D bioprinting encompasses additional complexities compared with non-biological printing such as 
the choice of materials and the technical challenges related to the sensitivity of the materials and 
living cells used as bioinks [205]. Hydrogels are often employed as bioinks since they are printable, 
biocompatible and able to maintain cell viability and activity due to their ability to store huge 
amounts of water (up to 99% w/w), which mimics features of cellular environment [218, 219]. 
Bioinks can be made from polymers of natural origin such as alginate [220], gelatine [198], collagen 
[221], fibrin [222], hyaluronic acid [223], chitosan [224] or agarose [225]; or it can be made from 
synthetic polymers including PEG [226] and Pluronic [227, 228]. The bioink employed in extrusion-
based bioprinting has to be stimuli-responsive and self-supporting during layer-by-layer fabrication 
[229]. The shear thinning property of hydrogels helps in the extrusion of the bioink, where the 
hydrogels behave as liquid under high shear stresses during extrusion, but can easily turn into semi-
solid gels, through thermal processes or post-print crosslinking [196]. It is important to evaluate the 
molecular weight, viscosity, gelation kinetics and stiffness of hydrogels used as a bioink for 3D 
bioprinting, [230]. Different types of hydrogels can be combined with various ratios to optimize the 
printing efficiency and resolution. Cross-linking of hydrogels is a critical step in the bioprinting 
process. This is why adding hydrogel precursors, which are reagents with chemically reactive, photo-
polymerisable groups, to the bioink is important to help gelation during printing with the aid of 
UV/visible light with or without the effect of temperature [194].  Examples of such hydrogel 
precursors include poly(ethylene glycol) methacrylate, poly(ethylene glycol) diacrylate, 
poly(ethylene glycol) acrylate and gelatine methacrylate (GelMA) [225, 231].  
In ophthalmology, the application of 3D bioprinting is still at its infancy and reported additive 
manufacturing for ophthalmic applications are very limited [211, 232]. However, this promising 
technology can be utilised to make corneas [196], ocular lenses [233] or other parts of the eye from 
the patient’s own cells. It is expected that scientists can print on demand intraocular lenses, 
glaucoma valves and ocular implants using 3D printing and hydrogels as bioinks [192]. Human 
corneal epithelial cells (HCECs) were successfully printed into cell-laden constructs of collagen, 
gelatine and alginate to generate a bioengineered corneal epithelium using extrusion-based 3D 
bioprinting technique. This collagen/gelatine/alginate material system proved to be a successful 
bioink with high bioprinting resolution, good mechanical properties, and high cell viability [196]. 
Each of the aforementioned 3D printing techniques could lend itself to a specific ocular tissue 
construction application. For instance, layered corneal structures can be obtained by extrusion-
based 3D bioprinting, with its ability to deposit multiple cell types with high cell density using 
multiple print heads. While fabrication of the limbal region would require the high resolution and 
speed of the ink-jet printing [211]. It is expected that the next generation 3D printed hydrogels will 
be adjusted to promote cell proliferation, differentiation and help induce extracellular matrix 
generation through release of cell-regulating factors [183]. 
6.4.2 3D printed drug delivery devices comprising ophthalmic gels  
A drug delivery device (DDD) is a prefabricated system intended to release the drug to the desired 
organ with maximum safety, effectiveness, and reliability [234]. Delivery of therapeutics to the back 
of the eye using conventional eye drops is difficult due to dilution and clearance by the lacrimal fluid, 
nasolacrimal drainage, the need to diffuse through the vitreous and overcome the various blood-
ocular barrier. These factors lead to poor ocular bioavailability of drugs and thus treatment failure  
[235, 236]. Intravitreal injections are used to deliver drugs to the posterior eye segment for 
treatment of diseases like age-related macular degeneration, diabetic retinopathy, and retinitis 
pigmentosa to reduce the risk of blindness [237]. However, intravitreal injections suffer from some 
complications such as increased intraocular pressure, intraocular haemorrhage and retinal 
detachment, together with poor patient incompliance [238]. Implantable ocular devices are only 
second to intravitreal injection when it comes to posterior segment drug delivery. They can maintain 
relatively high drug concentration at the target site with less side effects, yet have their own 
limitations [236].  
One type of ocular devices is the implantable pump systems, where drugs are incorporated into an 
ophthalmic gel.  The intake of biological fluids leads to swelling of the hydrogel and subsequent 
release of the drug in a controlled, continuous and sustained mode at the target sight [237].  
However, the confined nature and relatively small size of the human eye adds a spatial constrain to 
the use of ocular devices, which could be resolved through the development of Micro-Electro-
Mechanical System (MEMS) devices with drug-infused hydrogel systems [238, 239]. These MEMS 
devices have the advantage of controlled drug delivery rates despite their small size due to absence 
of the mechanical pump that is present in conventional pump systems [240]. 3D printing technology 
allows the construction of small, yet complex-structure drug delivery devices through layer-by-layer 
fabrication of structures with controlled porosity. These 3D printed DDDs are capable of holding 
therapeutics, including peptide nucleotides [241], and control their diffusion rate into the biological 
environment to achieve tailored drug release after implantation [242, 243]. Microbots are another 
example of these microscale DDDs that are used for the treatment of the anterior or posterior 
segment diseases via wireless manipulation and positioning of this tiny magnetic device. Fabrication 
of those complex shaped microbots is a challenge that can be further advanced through 3D printing 
techniques [244].   
3D printing can be used to fabricate the drug delivery device itself or the moulds used for casting of 
the DDD using soft lithography techniques [191, 245]. Lee et al. (2012) developed an implantable 
ocular DDD consisting of micro/nanochannels embedded between polydimethylsiloxane (PDMS) top 
and bottom covers with a drug reservoir. The drug was entrapped in a hydrogel that is enclosed in 
the PDMS drug reservoir, which was fabricated using the replica-moulding technique from a master 
mould [237]. The master mould for the top and bottom layers of the reservoir were fabricated using 
a 3D printing stereolithographic technique, where a UV laser beam is used to solidify a 
photosensitive monomer liquid resin layer-by-layer to build a 3D structure [246].    
6.5 New ocular applications for hydrogels  
6.5.1 Production of artificial corneas 
Human donor corneal transplants used to be the main treatment for severe corneal damage. 
However, corneal transplants have numerous limitations such as high cost and difficulty in storage. 
Moreover, patients might suffer from transplant rejection. Nowadays, new materials are developed 
as artificial corneas; hydrogels are biocompatible candidates that are used in ocular tissue 
engineering to replace defected corneas [247-249]. Poly (2-hydroxyethyl methacrylate) (PHEMA) is 
considered to be a potential substitute for the human cornea [248, 249]. Moreover, researchers 
have developed synthetic hydrogel corneal skirts with pores mimicking the structure under the 
limbal eye region to enhance cell binding, migration, adhesion, and elongation of human corneal 
fibroblasts, thus preventing keratoprosthesis extrusion [249-251].  
6.5.2 Corneal wound healing 
Ocular surface disorders that occur due to limbal stem cell deficiency (LSCD) can lead to impaired 
vision and blindness [252]. Currently, the main treatment of LSCD is amniotic membrane (AM) 
transplantation because of the anti-angiogenic and anti-inflammatory effects of the AM components 
[253-255]. However, the use of AM is often associated with limitations such as the need for 
extensive serological screening to ensure histological compatibility and to minimise the risk of 
possible disease transmission, impaired transparency, variable quality and poor mechanical strength 
[256, 257]. The biocompatible, viscoelastic properties of hydrogels render them a potential 
candidate to replace AM. Moreover, their structure can be modified to match body tissues [252].  
Various polymers have been utilised in tissue engineering of ocular surface through cross-linking to 
corneal stroma, such as poly(ethylene oxide) [258], alginates [259, 260] , gelatine [261], collagen 
[262-264], chitosan [262, 265, 266], fibrin [267, 268], keratin , cellulose and polymethacrylate [257, 
269]. Thermoreversible PLGA-PEG-PLGA triblock copolymer hydrogels exhibit an interconnecting 
network structure at body temperature. This network acts as a substrate promoting epithelial cell 
migration during wound healing and thus can be used to substitute AM transplant in corneal wound 
healing [270].  
7 Conclusion 
Recent estimates of the global cost of sight loss suggest an annual figure of over US$3 trillion.  The 
main disorders leading to sight loss are cataract, glaucoma, age-related macular degeneration (AMD) 
and diabetic retinopathy. Pharmaceutical formulation and drug delivery research have introduced 
promising eye treatments into the market; nevertheless, there remain unmet clinical needs and 
limitations associated with the performance of conventional ocular dosage forms. Compromised 
adherence and/or persistence with conventional eye drops that are applied topically to the surface 
of the eye is primarily related to the need to be administered once, twice (or even up to four times) 
daily, often as a combination of multiple drugs, to achieve their intended therapeutic purpose. Novel 
ophthalmic gels including nanogels, 3D printed hydrogels; medical devices tailored to deliver 
ophthalmic gels are promising to mitigate comorbidities associated with the aforementioned eye 
conditions. Production of artificial corneas and corneal wound healing are new and exciting areas of 
application of ophthalmic gels. 
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